FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients
NEW YORK –The Tisch MS Research Center of New York, the world’s largest independent research center focused on MS, announced the Phase II results of its FDA-approved stem cell treatment study. The research is a continuation of a Phase I trial, which was the first ever in the U.S. to receive FDA approval to investigate the injection of stem cells into the cerebrospinal fluid of MS patients. The Phase II trial showed improvements across multiple areas in progressive MS patients with significant disability.
These results suggest that stem cell treatments could be correlated with walking improvement, a finding that could have major implications for quality of life for progressive MS patients struggling with motor function.
The study also found a positive increase in gray matter volume among patients who began the trial with normalized gray matter above the 50th percentile. This indicates that stem cells could restore neuronal cells and potentially reverse cognitive decline in patients with less advanced disease progression. Additionally, patients who received the stem cell treatments showed improved bladder function, with 69% of patients showing improved post-void residual volume.
The stem cell treatments also resulted in notable biomarker changes in patients’ cerebrospinal fluid. Those who received the stem cell treatments showed decreased levels of the protein CCL2 (which is associated with inflammatory diseases like MS), as well as an increase in the protein MMP9 (a potential indicator of an increase in reparative microglial cells) compared to the control group. As a result, these biomarkers may provide a valuable mechanism to measure treatment response in future studies.
https://bioinformant.com/stem-cell-treatment-trial-shows-significant-improvements/
ارسال به دوستان